Inmune Bio, Inc. — Investor Relations & Filings
Filings indexed
571
across all filing types
Latest filing
2026-04-23
Proxy Solicitation & In…
Country
US
United States of America
Listing
US
INMB
Inmune Bio, Inc. is a clinical-stage biotechnology company that develops therapies by reprogramming the patient's innate immune system to fight disease. The company's pipeline is focused on treating cancer and neurodegenerative disorders, particularly Alzheimer's disease. Its lead product candidates include XPro1595, a selective inhibitor of soluble Tumor Necrosis Factor (TNF) for treating neuroinflammation, and INKmune®, a tumor-agnostic therapy designed to prime a patient's natural killer (NK) cells to attack cancer. Inmune Bio's clinical development approach prioritizes matching a drug's mechanism of action to patient biology and using patient-centric outcome metrics.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| DEF 14A - Inmune Bio, Inc. (0001711754) (Filer) | 2026-04-23 | English | |
| 8-K - INMUNE BIO, INC. (0001711754) (Filer) | 2026-02-27 | English | |
| 8-K - INMUNE BIO, INC. (0001711754) (Filer) | 2026-02-23 | English | |
| 8-K - INMUNE BIO, INC. (0001711754) (Filer) | 2026-02-19 | English | |
| 8-K Filing | 2026-02-13 | English | |
| 8-K Filing | 2026-01-27 | English |
Browse filings by year
10 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
6 filings
| |||||
| 35868237 | DEF 14A - Inmune Bio, Inc. (0001711754) (Filer) | 2026-04-23 | English | ||
| 32897132 | 8-K - INMUNE BIO, INC. (0001711754) (Filer) | 2026-02-27 | English | ||
| 32897130 | 8-K - INMUNE BIO, INC. (0001711754) (Filer) | 2026-02-23 | English | ||
| 32897131 | 8-K - INMUNE BIO, INC. (0001711754) (Filer) | 2026-02-19 | English | ||
| 31423861 | 8-K Filing | 2026-02-13 | English | ||
| 31423822 | 8-K Filing | 2026-01-27 | English | ||
|
2025
9 filings
| |||||
| 13050483 | CURRENT REPORT | 2025-12-23 | English | ||
| 13050482 | CURRENT REPORT | 2025-12-19 | English | ||
| 13050485 | PROSPECTUS SUPPLEMENT | 2025-12-19 | English | ||
| 13050484 | CURRENT REPORT | 2025-12-10 | English | ||
| 13050486 | AMENDMENT NO. 5 TO FORM 8-A12B | 2025-12-08 | English | ||
| 13050488 | CURRENT REPORT | 2025-12-08 | English | ||
| 13050487 | CURRENT REPORT | 2025-12-05 | English | ||
| 13050492 | CURRENT REPORT | 2025-12-03 | English | ||
| 13050489 | Director's Dealing 2025 | 2025-12-02 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
BIOVIE INC.
Develops drug therapies for neurological disorders and adva…
|
BIVI | US | Manufacturing |
|
BioXcel Therapeutics, Inc.
Biopharmaceutical company using AI to develop drugs for neu…
|
BTAI | US | Manufacturing |
|
Bioxel Pharma Inc.
Develops, manufactures, and markets taxane APIs, essential …
|
— | CA | Manufacturing |
|
BIOXYNE LIMITED
Life sciences company focused on probiotics, medicinal cann…
|
BXN | AU | Manufacturing |
|
B&K CORPORATION LIMITED
Innovative biopharma developing PDGF therapeutic drugs for …
|
2396 | HK | Manufacturing |
|
Black Diamond Therapeutics, Inc.
Develops precision oncology therapies targeting families of…
|
BDTX | US | Manufacturing |
|
BLAU FARMACÊUTICA S.A.
Multinational producer of high-complexity medications for h…
|
— | BR | Manufacturing |
|
Bliss GVS Pharma Limited
Global leader in suppository and pessary production for eme…
|
BLISSGVS | IN | Manufacturing |
|
Blis Technologies Limited
Develops and commercializes patented probiotic strains for …
|
BLT | NZ | Manufacturing |
|
Bloomage Biotechnology Corporation Limited
Global leader in hyaluronic acid and bioactive substance re…
|
688363 | CN | Manufacturing |
Inmune Bio, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34518/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34518 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34518 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34518 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34518}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Inmune Bio, Inc. (id: 34518)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.